IN8bio’s DeltEx DRI Doubles Glioblastoma Progression-Free Survival to 16.1 Months
INAB•IN8bio published Phase 1 INB-200 trial results demonstrating repeat-dose DeltEx DRI doubled median progression-free survival to 16.1 months versus a 6.9-month standard-of-care benchmark in newly diagnosed glioblastoma, with no dose-limiting toxicities reported. Repeat-dose patients also achieved median overall survival of 19.5 months, exceeding the ~14.6-month historical standard-of-care median.
1. Phase 1 Trial Results
In a frequency-escalation study, 13 newly diagnosed glioblastoma patients received 1 to 6 intracranial doses of DeltEx DRI alongside temozolomide. Across all cohorts median progression-free survival reached 9.9 months (43.5% improvement over a 6.9-month benchmark) and median overall survival in repeat-dose patients was 19.5 months versus ~14.6 months historically.
2. Safety Profile
DeltEx DRI was well tolerated with no dose-limiting toxicities, no cytokine release syndrome and no immune effector cell-associated neurotoxicity observed in any cohort.
3. Publication Milestone
These Phase 1 INB-200 results represent the first peer-reviewed clinical data for chemotherapy-resistant γδ T cell therapy in glioblastoma, marking a significant validation of the DeltEx platform in The Journal of Clinical Oncology.
4. Next Steps
IN8bio plans to advance DeltEx DRI into later-stage studies, with additional clinical data updates expected later this year to support potential regulatory discussions and broaden its solid tumor immunotherapy pipeline.
